Mechanisms, indications and results of salvage systemic therapy for sporadic and von Hippel-Lindau related hemangioblastomas of the central nervous system

Critical Reviews in Oncology/Hematology

Volumn 86, Issue 1, 2013, Pages 69-84

  Capitanio, Jody Filippo ^a   Mazza, Elena ^a   Motta, Micaela ^a   Mortini, Pietro ^a   Reni, Michele ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Anti angiogenetic drugs; Guidelines; HB follow up; Interferon alpha 2a; Pharmacologic treatment for HBs; Salvage systemic therapy; Semaxanib; Sporadic HB; Su5416; Thalidomide; Therapeutic options; Tyrosine kinase inhibitors; Vatalanib; VHL related HB

Indexed keywords

ALPHA2A INTERFERON; BEVACIZUMAB; GADOLINIUM; HYPOXIA INDUCIBLE FACTOR; SEMAXANIB; SUNITINIB; THALIDOMIDE; VASCULOTROPIN; VATALANIB; VON HIPPEL LINDAU PROTEIN;

ACUTE LEUKEMIA; ADVANCED CANCER; AMENORRHEA; AMNESIA; ANEMIA; ARTHRALGIA; ARTIFICIAL EMBOLISM; BLEEDING; CANCER CHEMOTHERAPY; CANCER SCREENING; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM TUMOR; CHEMOTHERAPY INDUCED EMESIS; DEPRESSION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIGITAL SUBTRACTION ANGIOGRAPHY; DNA SEQUENCE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FAMILY HISTORY; FATIGUE; FLU LIKE SYNDROME; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; HAIRY CELL LEUKEMIA; HEMANGIOBLASTOMA; HEMANGIOPERICYTOMA; HISTOPATHOLOGY; HUMAN; KAPOSI SARCOMA; KIDNEY CARCINOMA; KIDNEY CYST; LASER COAGULATION; LETHARGY; LEUKOPENIA; LIVER HEMANGIOMA; MELANOMA; MENINGIOMA; MULTIPLE CYCLE TREATMENT; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NAUSEA; NEUROIMAGING; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CYST; PHEOCHROMOCYTOMA; POLYCYTHEMIA; PRURITUS; RADIOSURGERY; REAL TIME POLYMERASE CHAIN REACTION; RETINA; RETINA MACULA CYSTOID EDEMA; REVIEW; SALVAGE THERAPY; SIDE EFFECT; SOUTHERN BLOTTING; STEREOTACTIC RADIOSURGERY; SYSTEMIC THERAPY; TUMOR CLASSIFICATION; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE; VON HIPPEL LINDAU GENE; WOUND HEALING IMPAIRMENT;

ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CEREBELLAR NEOPLASMS; HEMANGIOBLASTOMA; HUMANS; SALVAGE THERAPY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VON HIPPEL-LINDAU DISEASE;

EID: 84875056306     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.10.001     Document Type: Review

References (147)

1. Filling-Katz M.R., Choyke P.L., Oldfield E., et al. Central nervous system involvement in von Hippel-Lindau disease. Neurology 1991, 41:41-46.
2. Couch V., Lindor N.M., Karnes P.S., Michels V.V. von Hippel-Lindau disease. Mayo Clinic Proceedings 2000, 75:265-272.
3. Hes F.J., van der Luijt R.B. von Hippel-Lindau disease: protocols for diagnosis and periodical clinical monitoring National von Hippel-Lindau Disease Working Group. Nederlands Tijdschrift Voor Geneeskunde 2000, 144:505-509. [in Dutch].
4. Wanebo J.E., Lonser R.R., Glenn G.M., Oldfield E.H. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. Journal of Neurosurgery 2003, 98:82-94.
5. Maher E.R., Kaelin W.G. von Hippel-Lindau disease. Medicine 1997, 76:381-391.
6. Richard S., Campello C., Taillandier L., Parker F., Resche F. Hemangioblastoma of the central nervous system in von Hippel-Lindau disease. Journal of Internal Medicine 1998, 243:547-553.
7. Neumann H.P., Eggert H.R., Weigel K., Friedburg H. Hemangioblastomas of the central nervous system. A 10-year study with special reference to von Hippel-Lindau syndrome. Journal of Neurosurgery 1989, 70:24.
8. Maddock I.R., Moran A., Maher E.R., et al. A genetic register for von Hippel-Lindau disease. Journal of Medical Genetics 1996, 33:120-127.
9. Maher E.R. von Hippel-Lindau disease. European Journal of Cancer 1994, 30A:1987-1990.
10. Solomon D., Schwartz A. Renal pathology in von Hippel-Lindan disease. Human Pathology 1996, 19:1072-1079.
11. Christenson P.J., Craig J.P., Bibro M.C., O' Connell P. Cysts containing renal cell carcinoma in von Hippel-Lindau disease. Journal of Urology 1982, 128:798-800.
12. Malek R.S., Omess P.J., Benson R.C., Zincke H. Renal cell carcinoma in VHL syndrome. American Journal of Medicine 1987, 82:236-238.
13. Ibrahim R.E., Weinberg D.S., Weidner N. Atypical cysts and carcinoma of the kidneys in the phacomatoses. Cancer 1989, 63:148-157.
14. Poston C.D., Jaffe G.S., Lubensky I.A., et al. Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. Journal of Urology 1995, 153:22-26.
15. Hough D.M., Stephens D.H., Johnson C.D., Binkovitz L.A. Pancreatic lesions in von Hippel-Lindau disease: prevalence, clinical significance, and CT findings. American Journal of Roentgenology 1994, 162:1091-1094.
16. Blamires T.L., Maher E.R. Choroid plexus papilloma. A new presentation of VHL disease. Eye 1992, 6:90-92.
17. Neumann H.P. Das v. Hippel-Lindau-Syndrom (The von Hippel-Lindau syndrome). Deutsche Medizinische Wochenschrift 1991, 116:28-34.
18. Kanno H., Kondo K., Ito S., et al. Somatic mutations of the VHL tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Research 1994, 54:4845-4847.
19. Latif F., Tory K., Gnarra J., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260:1317-1320.
20. Lee J.Y., Dong S.M., Park W.S., et al. Loss of heterozygosity and somatic mutation of the VHL suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Research 1998, 58:504-508.
21. Vortmeyer A.O., Gnarra J.R., Emmert-Buck M.R., Katz D., Linehan W.M., Oldfield E.H. von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Human Pathology 1997, 28:540-543.
22. Melmon K.L., Rosen S.W. Lindau's disease: review of literature and study of a large kindred. American Journal of Medicine 1964, 36:595-617.
23. Hes F.J., van der Luijt R.B., Janssen A.L., et al. Frequency of von Hippel-Lindau germline mutations in classic and non-classic von Hippel-Lindau disease identified by DNA sequencing, Southern blot analysis and multiplex ligation-dependent probe amplification. Clinical Genetics 2007, 72(August (2)):122-129.
24. Santarpia L., Sarlis N.J., Santarpia M., Sherman S.I., Trimarchi F., Benvenga S. Mosaicism in von Hippel-Lindau disease: an event important to recognize. Journal of Cellular and Molecular Medicine 2007, 11(November-December (6)):1408-1415.
25. Chen F., Kishida T., Yao M., et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Human Mutation 1995, 5:66-75.
26. Gallou C., Joly D., Mejean A., et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Human Mutation 1999, 13:464-475.
27. Neumann H.P., Bender B.U. Genotype-phenotype correlations in von Hippel-Lindau disease. Journal of Internal Medicine 1998, 243:541-545.
28. Barontini M., Dahia P.L.M. Best Practice and Research Clinical Endocrinology and Metabolism 2010, 24:401-413.
29. Rachinger J., Buslei R., Prell J., Strauss C. Solid haemangioblastomas of the CNS: a review of 17 consecutive cases. Neurosurgical Review 2009, 32:37-48.
30. Piribauer M., Czech T., Dieckmann K., et al. Stabilization of a progressive hemangioblastoma under treatment with thalidomide. Journal of Neuro-Oncology 2004, 66:295-299.
31. Omulecka A., Lach B., Alwasiak J., Gregor A. Immunohistochemical and ultrastructural studies of stromal cells in hemangioblastoma. Folia Neuropathologica 1995, 33(1):41-50.
32. Lonser R.R., Glenn G.M., Walther M., et al. von Hippel-Lindau disease. Lancet 2003, 361(9374):2059-2067.
33. Duan D.R., Pause A., Burgess W.H., et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 1995, 269(5229):1402-1406.
34. Kaelin W.G. Molecular basis of the VHL hereditary cancer syndrome. Nature Reviews Cancer 1995, 2(9):673-682.
35. Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumour suppressor protein VHL targets hypoxia inducible factors for oxygen-dependent proteolysis. Nature 1999, 399(6733):271-275.
36. Pause A., Lee S., Worrell R.A., et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL2, a member of the Cdc53 family of proteins. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(6):2156-2161.
37. 2 homeostasis by hypoxia-inducible factor 1. Annual Review of Cell and Developmental Biology 1999, 15:551-578.
38. Semenza G. Perspectives on oxygen sensing. Cell 1999, 98:281-284.
39. Wenger R. Mammalian oxygen sensing, signaling and gene regulation. Journal of Experimental Biology 2000, 203:1253-1263.
40. Zhu H., Bunn F. Oxygen sensing and signaling: impact on the regulation of physiologically important genes. Respiration Physiology 1999, 115:239-247.
41. Maynard M.A., Ohh M. von Hippel-Lindau Tumor Suppressor Protein and Hypoxia-Inducible Factor in Kidney Cancer. American Journal of Nephrology 2004, 24:1-13.
42. Carmeliet P., Dor Y., Herbert J.M., et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998, 394(6692):485-490.
43. Reifenberger G., Reifenberger J., Bilzer T., Wechsler W., Collins V.P. Coexpression of transforming growth factor-alpha and epidermal growth factor receptor in capillary hemangioblastomas of the central nervous system. American Journal of Pathology 1995, 147(2):245-250.
44. Park D.M., Zhuang Z., Chen L., et al. von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Medicine 2007, 4(2):e60.
45. Ammerman J.M., Lonser R.R., Dambrosia J., Butman J.A., Oldfield E.H. Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease: implications for treatment. Journal of Neurosurgery 2006, 105(August (2)):248-255.
46. Butman J.A., Marston Linehan W., Lonser R.R. Neurologic manifestations of von Hippel-Lindau disease. The Journal of the American Medical Association 2008, 300(11):1334-1342.
47. Friedrich C.A. von Hippel-Lindau syndrome. Cancer 1999, 86:2478-2482.
48. Adegbite A.B., Rozdilsky B., Varughese G. Supratentorial capillary hemangioblastoma presenting with fatal spontaneous intracerebral hemorrhage. Neurosurgery 1983, 12:327.
49. Yu J.S., Short M.P., Schumacher J., Chapman P.H. Intramedullary hemorrhage in spinal cord hemangioblastoma. Report of two cases. Journal of Neurosurgery 1994, 81:937.
50. Gläsker S., Van Velthoven V. Risk of hemorrhage in hemangioblastomas of the central nervous system. Neurosurgery 2005, 57(July (1)):71-76.
51. Ros de San Pedro J., Alarcón Rodríguez F., Ferri ñíguez B., et al. Neurosurgical Review 2010, 33:11-26.
52. Cerejo A., Vaz R., Feyo P.B., Cruz C. Spinal cord hemangioblastoma with subarachnoid haemorrhage. Neurosurgery 1990, 27:991.
53. Kormos R.L., Tucker W.S., Bilbao J.M., Gladstone R.M. Subarachnoid haemorrhage due to a spinal cord hemangioblastoma: case report. Neurosurgery 1980, 6:657.
54. Choyke P.L., Glenn G.M., McClennan M.W., Patronas N.J., Linehan W.M., Zbar B. von Hippel Lindau disease: genetic, clinical and imaging features. Radiology 1995, 194:629-642.
55. Waldmann T.A., Levin E.H., Baldwin M. The association of polycythemia with a cerebellar hemangioblastoma. The production of an erythropoiesis stimulating factor by the tumour. American Journal of Medicine 1961, 31:318.
56. Zec N., Cera P., Towfighi J. Extramedullary hematopoiesis in cerebellar HBs. Neurosurgery 1991, 29:34.
57. Roonprapunt C., Silvera V.M., Setton A., Freed D. Surgical management of isolated HBs of the spinal cord. Neurosurgery 2001, 49:321.
58. http://www.vhl.org/handbook.
59. Tampieri D., Leblanc R., TerBrugge K. Preoperative embolization of brain and spinal hemangioblastomas. Neurosurgery 1993, 33:502-505.
60. Eskridge J.M., McAuliffe W., Harris B., Kim D.K., Scott J., Winn H.R. Preoperative endovascular embolization of craniospinal hemangioblastomas. American Journal of Neuroradiology 1996, 17:525-531.
61. Satoshi U., Hidehiro O., Kimitoshi S., Satoru S., Sachio S., Kiyotaka F. Fluorescence diagnosis of tumor cells in hemangioblastoma cysts with 5-aminolevulinic acid. Journal of Neurosurgery 2010, 112:130-132.
62. Jawahar A., Kondziolka D., Garces Y.I., Flickinger J.C., Pollock B.E., Lunsford L.D. Stereotactic radiosurgery for hemangioblastomas of the brain. Acta Neurochirurgica 2000, 142:641-644.
63. Smalley S.R., Schomberg P.J., Earle J.D., Laws E.R., Scheithauer B.W., O'Fallon J.R. Radiotherapeutic considerations in the treatment of hemangioblastomas of the central nervous system. International Journal of Radiation Oncology, Biology, Physics 1990, 18(May (5)):1165-1171.
64. Patrice S.J., Sneed P.K., Flickinger J.C., et al. Radiosurgery for hemangioblastoma: results of a multiinstitutional experience. International Journal of Radiation Oncology, Biology, Physics 1996, 35(June (3)):493-499.
65. Sung D.I., Chang C.H., Harisiadis L. Cerebellar hemangioblastomas. Cancer 1982, 49(February (3)):553-555.
66. Smalley S.R., Schray M.F., Laws E.R., O'Fallon J.R. Adjuvant radiation therapy after surgical resection of solitary brain metastasis: association with pattern of failure and survival. International Journal of Radiation Oncology, Biology, Physics 1987, 13(November (11)):1611-1616.
67. Chang S.D., Meisel J.A., Hancock S.L., Martin D.P., McManus M., Adler J.R. Treatment of hemangioblastomas in von Hippel-Lindau disease with linear accelerator-based radiosurgery. Neurosurgery 1998, 43:28-35.
68. Matsunaga S., Shuto T., Inomori S., Fujino H., Yamamoto I. Gamma knife radiosurgery for intracranial haemangioblastomas. Acta Neurochirurgica 2007, 149:1007-1013.
69. Niemela M., Lim Y.J., Soderman M., et al. Gamma knife radiosurgery in 11 hemangioblastomas. Journal of Neurosurgery 1996, 85:591-596.
70. Moss J.M., Choi C.Y., Adler J.R., Soltys S.G., Gibbs I.C., Chang S.D. Stereotactic radiosurgical treatment of cranial and spinal hemangioblastomas. Neurosurgery 2009, 65:79-85.
71. Park Y.S., Chang J.H., Chang J.W., Chung S.S., Park Y.G. Gamma knife surgery for multiple hemangioblastomas. Journal of Neurosurgery 2005, 102:97-101.
72. Tago M., Terahara A., Shin M., et al. Gamma knife surgery for hemangioblastomas. Journal of Neurosurgery 2005, 102:171-174.
73. Wang E.M., Pan L., Wang B.J., et al. The long-term results of gamma knife radiosurgery for hemangioblastomas of the brain. Journal of Neurosurgery 2005, 102:225-229.
74. Sayer F.T., Nguyen J., Starke R.M., Yen C., Sheehan J.P. Gamma knife radiosurgery for intracranial hemangioblastomas - outcome at 3 years. World Neurosurgery 2011, 75(1):99-105.
75. Ebert E.M., Albert D.M. The phakomatoses. Principles of practical ophthalmology 1974, vol. 5:3310-3313. W.B. Saunders Company, Philadelphia.
76. Nicholson D.H., Green W.R., Kenyon K.R. Light and electron microscopic study of early lesions in angiomatosis retinae. American Journal of Ophthalmology 1976, 82:193-204.
77. Apple D.J., Goldber M.F., Wyhinny G. Argon laser treatment of von Hippel Lindau retinal angiomas. II: histopathology of treated lesions. Archives of Ophthalmology 1974, 92:126-130.
78. Knutsson K.A., De Benedetto U., Querques G., Del Turco C., Bandello F., Lattanzio R. Primitive retinal vascular abnormalities: tumors and telangiectasias. Ophthalmologica 2012, 228:67-77.
79. Dollfus H., Massin P., Taupin P., et al. Retinal hemangioblastoma in von Hippel Lindau disease: a clinical and molecular study. Investigative Ophthalmology and Visual Science 2002, 43:3067-3074.
80. Hasselblatt M., Jeibmann A., Gerss J., et al. Cellular and reticular variants of haemangioblastoma revisited: a clinicopathologic study of 88 cases. Neuropathology and Applied Neurobiology 2005, 31(December (6)):618-622.
81. Flamme I., Krieg M., Plate K.H. Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2alfa. American Journal of Pathology 1998, 153:25-29.
82. Hernberg M., Pyrhonen S., Muhonen T. Regimens with or without interferon-α as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. Journal of Immunotherapy 1999, 22:145-154.
83. Sidky Y.A., Borden E.C. Inhibition of angiogenesis by interferons: effects on tumor and lymphocyte-induced vascular responses. Cancer Research 1987, 47:5155-5161.
84. Frassoldati A., Lamparelli T., Federico M., et al. Hairy cell leukemia: a clinical review based on 725 cases of the Italian cooperative group (ICGHCL). Leukemia and Lymphoma 1994, 13:307-316.
85. Ezekowitz R.A.B., Mulliken J.B., Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. New England Journal of Medicine 1992, 326:1456-1463.
86. Brouty-Boye D., Zetter B.R. Inhibition of cell motility by interferon. Science 1980, 208:516-518.
87. Sidky Y.A., Borden E.C. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Research 1987, 47:5155-5161.
88. Dvorak H.F., Gresser I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. Journal of the National Cancer Institute 1989, 81:497-502.
89. von Marschall Z., Scholz A., Cramer T., et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. Journal of the National Cancer Institute 2003, 95:437-448.
90. White C.W., Sondheimer H.M., Crouch E.C., Wilson H., Fan L.L. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. New England Journal of Medicine 1989, 320:1197-1200.
91. Folkman J. Successful treatment of an angiogenic disease. New England Journal of Medicine 1989, 320:1211-1212.
92. Singh R.K., Gutman M., Bucana C.D., Sanchez R., Llansa N., Fidler I.J. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:4562-4566.
93. Ozawa S., Shinohara H., Kanayama H.O., et al. Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha. Neoplasia 2001, 3:154-164.
94. Niemela M., Maenpaa H., Salven P., et al. Interferon α-2a therapy in 18 hemangioblastomas. Clinical Cancer Research 2001, 7:510-516.
95. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., Smith T.J., Borden E.C., Blum R.H. Interferon a-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. Journal of Clinical Oncology 1996, 14:7-17.
96. Pyrhonen S., Salminen E., Ruutu M., et al. Prospective randomized trial of interferon α-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. Journal of Clinical Oncology 1999, 17:2859-2867.
97. Millauer B., Wizigmann-Voos S., Schnurch H., et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993, 72:835-846.
98. Quinn T.P., Peters K.G., De Vries C., Ferrara N., Williams L.T. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:7533-7537.
99. Peters K., Werner S., Whitsett J., Williams L. Targeted expression of a dominant negative FGF receptor blocks branching morphogenesis and epithelial differentiation of the mouse lung. EMBO Journal 1994, 13:3296-3301.
100. Millauer B., Shawver L.K., Plate K.H., Risau W., Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994, 367:576-579.
101. Millauer B., Longhi M.P., Plate K.H., et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Research 1996, 56:1615-1620.
102. Ferrara N., Carver-Moore K., Chen H., et al. Heterozygous embryonic lethality induced by targeted inactivation of VEGF gene. Nature 1996, 380:439-442.
103. Saleh M., Stacker S.A., Wilks A.F. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Research 1996, 56:393-401.
104. Claffey K.P., Brown L.F., del Aguila L.F., et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Research 1996, 56:172-181.
105. Kim K.J., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
106. Asano M., Yukita A., Matsumoto T., Kondo S., Suzuki H. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor 121. Cancer Research 1995, 55:5296-5301.
107. Rockwell P., Neufeld G., Glassman A., Caron D., Goldstein N. In vitro neutralization of vascular endothelial growth factor activation of Flk-1 by a monoclonal antibody. Molecular and Cellular Differentiation 1995, 3:91-109.
108. Rockwell P., Witte L., Hicklin D., Pytowski B., Goldstein N.I. Antitumor activity of anti-Flk-1 monoclonal antibodies. Proceedings of the American Association of Cancer Research 1997, 38:266.
109. Cushman C., Escobedo J., Parry T.J., et al. Ribozyme inhibition of VEGF-mediated endothelial cell proliferation in cell culture and VEGF-induced angiogenesis in a rat corneal model. Angiogenesis inhibitors and other novel therapeutic strategies for ocular diseases of neovascularization 1996, International Business Communications, USA.
110. Fong T.A., Shawver L.K., Sun L., et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Research 1999, 59(January (1)):99-106.
111. Madhusudan A., Deplanque G., Braybrooke, et al. Antiangiogenic therapy for von Hippel-Lindau disease. The Journal of the American Medical Association 2004, 291(8):943-944.
112. Miller A.B., Hoogstraten B., Winkler A. Reporting results of cancer treatment. Cancer 1981, 47:207-214.
113. Richard S., Croisille L., Yvart J., et al. Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with antivascular endothelial growth factor receptor therapy. Blood 2002, 99:3851-3853.
114. O'Donnell A., Trigo J., Banerji U. A phase I trial of the VEGF inhibitor SU5416, incorporating dynamic contrast MRI assessment of vascular permeability. Proceedings of the ASCO 2000, 19:685.
115. Stopeck A. Proceedings of the ASCO 2000, 19:802.
116. Miles S., Arasteh K., Gill P., et al. Proceedings of the ASCO 2000, 19:683.
117. Rosen L., Hannah A., Rosen P., et al. Proceedings of the AACR 2000, 41:2087.
118. Rosen P. Proceedings of the AACR 2000, 19:5D.
119. Smolich B.D., Yuen H.A., et al. The anti-angiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood 2001, 97:1413-1421.
120. Waldmann T.A., Levin, Baldwin M. The association of polycythemia with cerebellar hemangioblastoma. American Journal of Medicine 1961, 31:318-324.
121. Trimble M., Caro J., Talalla A., Brain M. Secondary erythrocytosis is due to a cerebellar hemangio-blastoma: demonstration of erythropoietin mRNA in the tumor. Blood 1991, 78:599-601.
122. Krieg M., Marti H.H., Plate K.H. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. Blood 1998, 92:3388-3393.
123. Vortmeyer A.O., Emmert-Buck M.R., et al. von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Human Pathology 1998, 28:540-543.
124. Aiello L.P., George D.J., Cahill M.T., et al. Rapid and durable recovery of visual function in a patient with von Hippel-Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology 2002, 109:1745-1751.
125. Girmens J.F., Erginay A., Massin P., et al. Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. American Journal of Ophthalmology 2003, 136:194-196.
126. Schuch G., de Wit M., Holtje J., et al. Case 2. Hemangioblastomas: diagnosis of von Hippel-Lindau disease and antiangiogenic treatment with SU5416. Journal of Clinical Oncology 2005, 23:3624-3626.
127. Wood J.M., Bold G., Buchdunger E., et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Research 2000, 60:2178-2189.
128. Hrisomalos F.N., Maturi R.K., Veena P. Long-term use of intravitreal bevacizumab (Avastin) for the treatment of von Hippel-Lindau associated retinal hemangioblastomas. The Open Ophthalmology Journal 2010, 4:66-69.
129. Keifer J.A., Guttridge D.C., Baldwin A.S. Journal of Biological Chemistry 2001, 276(June (25)):22382-22387. [Epub April 10, 2001].
130. Marriott J.B., Muller G., Dalgleish A.G. Immunology Today 1999, 20:538-540.
131. Schuler U., Ehninger G. Drug Safety 1995, 12:364-369.
132. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., Kaplan G. Journal of Experimental Medicine 1991, 173:699-703.
133. Tavares J.L., Wangoo A., Dilworth P., Marshall B., Kotecha S., Shaw R.J. Respiratory Medicine 1997, 91:31-39.
134. Moller D.R., Wysocka M., Greenlee B.M., et al. Journal of Immunology 1997, 159:5157-5161.
135. Corral L.G., Haslett P.A., Muller G.W., et al. Journal of Immunology 1999, 163:380-386.
136. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:4082-4085.
137. Kenyon B.M., Browne F., D'Amato R.J. Experimental Eye Research 1997, 64:971-978.
138. Keifer J.A., Guttridge D.C., Ashburner B.P., Baldwin A.S. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. Journal of Biological Chemistry 2001, 276:22382-22387.
139. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. Journal of Experimental Medicine 1991, 173:699-703.
140. Li X., Liu X., Wang J., et al. Thalidomide downregulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Research 2003, 23:2481-2487.
141. Fujita J., Mestre J.R., Zeldis J.B., Subbaramaiah K., Dannenberg A.J. Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase 2. Clinical Cancer Research 2001, 7:3349-3355.
142. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S. Science 1998, 281:1680-1683.
143. Guttridge D.C., Albanese C., Pestell R.G., Baldwin A.S. Molecular and Cellular Biology 1999, 19:5785-5799.
144. Mayo M.W., Baldwin A.S. Biochimica et Biophysica Acta 2000, 1470:M55-M62.
145. Kumar S., Witzig T.E., Rajkumar S.V. Thalidomide: current role in the treatment of non-plasma cell malignancies. Journal of Clinical Oncology 2004, 22:2477-2488.
146. Piribauer M., Czech T., Dieckmann K., et al. Stabilization of a progressive HB under treatment with thalidomide. Journal of Neuro-Oncology 2004, 66:295-299.
147. Sardi I., Sanzo M., Giordano F., et al. Monotherapy with thalidomide for treatment of spinal cord hemangioblastomas in a patient with von Hippel-Lindau disease. Pediatr Blood Cancer 2009, 53:464-467.